Veru
Yahoo Finance • 3 days ago
Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity
MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today anno... Full story
Yahoo Finance • last month
Veru outlines Phase III plans for enobosarm and signals upcoming FDA clarity on lean mass preservation in obesity treatment
Earnings Call Insights: Veru Inc. (VERU) Q3 2025 MANAGEMENT VIEW * CEO Mitchell S. Steiner reported that Veru is focusing its late clinical-stage biopharmaceutical efforts on cardiometabolic and inflammatory diseases, emphasizing two c... Full story
Yahoo Finance • last month
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-... Full story
Yahoo Finance • 2 months ago
Veru Q3 2025 Earnings Preview
* Veru (NASDAQ:VERU [https://seekingalpha.com/symbol/VERU]) is scheduled to announce Q3 earnings results on Tuesday, August 12th, before market open. * The consensus EPS Estimate is -$0.50 [https://seekingalpha.com/symbol/VERU/earnings... Full story
Yahoo Finance • 2 months ago
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced... Full story
Yahoo Finance • 2 months ago
Veru announces 1-for-10 reverse stock split
* Veru (NASDAQ:VERU [https://seekingalpha.com/symbol/VERU]) on Wednesday announced a reverse stock split at a ratio of 1-for-10, effective August 11, 2025. * At the effective time, all outstanding stock options, stock appreciation righ... Full story
Yahoo Finance • 2 months ago
Veru Announces Reverse Stock Split
MIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today annou... Full story
Yahoo Finance • 2 months ago
Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th
MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced... Full story
Yahoo Finance • 2 months ago
Veru to Participate in the 2025 BTIG Virtual Biotech Conference
MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today annou... Full story
Yahoo Finance • 3 months ago
InvestingPro's Fair Value model captures 67% upside in Veru shares
When InvestingPro’s Fair Value models identified (NASDAQ:VERU) as significantly undervalued in January 2024, the healthcare company’s stock was trading at just $0.41. Today, that analysis has proven remarkably accurate, with shares deliver... Full story
Yahoo Finance • 3 months ago
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly... Full story
Yahoo Finance • 4 months ago
Veru to Participate in the Virtual BTIG Obesity Health Forum
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today annou... Full story
Yahoo Finance • 4 months ago
Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave
[Financial Stock Market Technology] koto_feja FTSE Russell has released a preliminary list of companies [https://www.lseg.com/content/dam/ftse-russell/en_us/documents/other/ru3000-additions-20250523.pdf]set to join or leave the Russell 30... Full story
Yahoo Finance • 4 months ago
Beyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vitals Farms to leave
[Financial Stock Market Technology] koto_feja FTSE Russell released a preliminary list of companies set to join or leave the Russell Microcap Index as part of its 2025 annual reconstitution. The consumer staple companies set to join the... Full story
Yahoo Finance • 4 months ago
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and safety data, enobosarm 3... Full story
Yahoo Finance • 5 months ago
Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
MIAMI, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today anno... Full story
Yahoo Finance • 6 months ago
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today anno... Full story
Yahoo Finance • 7 months ago
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical... Full story
Yahoo Finance • 8 months ago
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% less lean mass than patient... Full story
Yahoo Finance • 2 years ago
Veru Announces Proposed Public Offering of Common Stock
Veru Inc. MIAMI, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology and viral-induced acute r... Full story
